Results for tag: "Brivanib"

Brivanib is an oncology drug used to treat advanced renal cell carcinoma (RCC). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Brivanib is typically used in combination with other drugs, such as interferon alfa or sunitinib, to treat advanced RCC. It is also used to treat hepatocellular carcinoma (HCC) and gastrointestinal stromal tumors (GIST). Brivanib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2013. It is currently marketed by Bristol-Myers Squibb and is available in the United States, Europe, and other countries. The Brivanib market is highly competitive, with several companies offering similar drugs. These include Pfizer, Novartis, Merck, AstraZeneca, and Eli Lilly. Other companies, such as Boehringer Ingelheim, are also developing drugs that target the same proteins as Brivanib. Show Less Read more